Ameluz: new photodynamic therapy option in actinic keratosis

Ameluz (5-aminolaevulinic acid) is a photosensitising agent for use in photodynamic therapy of mild to moderate actinic keratosis of the face and scalp.

The efficacy and tolerability of Ameluz (5-aminolaevulinic acid) are dependent on the type of light source used following application of the gel


Following topical application, 5-aminolaevulinic acid (ALA) is metabolised to protoporphyrin IX, a photosensitiser for photodynamic therapy (PDT). This compound accumulates intracellularly in the treated actinic keratosis lesions where it is activated by illumination with red light of a suitable wavelength and energy. This triggers the formation of reactive oxygen species which cause damage to cellular components and eventually destroy the target cells.1


Single-blind study

The efficacy and tolerability of ALA (78mg/g gel) was compared with that of methyl-5-aminolaevulinate (MAL, 160mg/g cream) or placebo in a randomised, observer-blind study involving 571 adults with 4–8 mild to moderate actinic keratosis lesions on the face or scalp. Patients underwent one PDT session, repeated once after 12 weeks if residual lesions remained.1,2

ALA was superior to both placebo and MAL in terms of the primary endpoint, complete patient clearance 12 weeks after the last PDT (78.2% versus 17.1% [p<0.0001] and 64.2% [p<0.05], respectively). In addition, lesion complete clearance rates were greater for ALA than for placebo or MAL (90.4% versus 37.1% and 83.2%, respectively).1,2 

Double-blind study

In a double-blind study of similar design (n=122), ALA was significantly more effective than placebo in terms of complete patient clearance rates (64% versus 11%; p<0.0001) and lesion complete clearance rates (81% versus 22%) 12 weeks after the last PDT.3

Efficacy and tolerability dependent on light source

In both studies, significant differences in efficacy rates and adverse event profiles were observed for the two light sources, in favour of narrow spectrum sources for efficacy and broad spectrum sources for tolerability.1-3


  1. Ameluz Summary of Product Characteristics, December 2011
  2. Dirschka T et al. Br J Dermatol 2012; 166: 137-46.
  3. Szeimies R-M et al. Br J Dermatol 2010; 163: 386-94.

View Ameluz drug record

Further information: Spirit Healthcare

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregnant woman having an ultrasound scan with a female sonographer

Valproate prescribing: plan for new regulatory measures without delay, instructs MHRA

A National Patient Safety Alert (NatPSA) has been issued...